688197 首药控股-U
午间休市 05-22 11:29:40
资讯
新帖
简况
每周股票复盘：首药控股（688197）SY-5007获益于国产先发优势
证券之星 · 05-17
每周股票复盘：首药控股（688197）SY-5007获益于国产先发优势
【机构调研记录】金鹰基金调研首药控股
证券之星 · 05-15
【机构调研记录】金鹰基金调研首药控股
【机构调研记录】东方基金调研达瑞电子、首药控股
证券之星 · 05-15
【机构调研记录】东方基金调研达瑞电子、首药控股
首药控股：5月1日接受机构调研，海通证券、兴业基金等多家机构参与
证券之星 · 05-14
首药控股：5月1日接受机构调研，海通证券、兴业基金等多家机构参与
首药控股（688197）披露2025年度持续督导跟踪报告，5月6日股价上涨0.78%
证券之星 · 05-06
首药控股（688197）披露2025年度持续督导跟踪报告，5月6日股价上涨0.78%
每周股票复盘：首药控股（688197）营收增119.88%净亏损收窄
证券之星 · 05-02
每周股票复盘：首药控股（688197）营收增119.88%净亏损收窄
首药控股（688197）2026年一季报简析：营收上升亏损收窄
证券之星 · 04-19
首药控股（688197）2026年一季报简析：营收上升亏损收窄
每周股票复盘：首药控股（688197）股东户数增11.6%
证券之星 · 04-19
每周股票复盘：首药控股（688197）股东户数增11.6%
首药控股（688197）披露2025年年度报告，4月17日股价下跌1.81%
证券之星 · 04-17
首药控股（688197）披露2025年年度报告，4月17日股价下跌1.81%
首药控股：第一季度净利润亏损1509.08万元
证券之星 · 04-17
首药控股：第一季度净利润亏损1509.08万元
首药控股跌3.3% 2022年上市募15亿中信建投保荐
中金财经 · 03-12
首药控股跌3.3% 2022年上市募15亿中信建投保荐
每周股票复盘：首药控股（688197）调整JAK2抑制剂研发合作获8300万元
证券之星 · 03-08
每周股票复盘：首药控股（688197）调整JAK2抑制剂研发合作获8300万元
首药控股（688197）披露关于调整JAK2抑制剂类抗肿瘤新药合作研发模式的公告，3月5日股价上涨1.29%
证券之星 · 03-05
首药控股（688197）披露关于调整JAK2抑制剂类抗肿瘤新药合作研发模式的公告，3月5日股价上涨1.29%
每周股票复盘：首药控股（688197）董事李庭因股东单位内部安排离任
证券之星 · 03-01
每周股票复盘：首药控股（688197）董事李庭因股东单位内部安排离任
首药控股（688197）披露董事离任公告，2月27日股价上涨0.74%
证券之星 · 02-27
首药控股（688197）披露董事离任公告，2月27日股价上涨0.74%
首药控股（688197）披露核心技术人员退休离任公告，2月24日股价下跌3.84%
中金财经 · 02-24
首药控股（688197）披露核心技术人员退休离任公告，2月24日股价下跌3.84%
首药控股跌3.84% 2022年上市募15亿中信建投保荐
中金财经 · 02-24
首药控股跌3.84% 2022年上市募15亿中信建投保荐
首药控股2026年关注点：业绩增长与核心产品审评进展
经济观察网 · 02-13
首药控股2026年关注点：业绩增长与核心产品审评进展
每周股票复盘：首药控股（688197）SY-9453获临床试验批准
证券之星 · 02-08
每周股票复盘：首药控股（688197）SY-9453获临床试验批准
首药控股(688197.SH)：MAT2A抑制剂SY-9453获得药物临床试验批准通知书
智通财经 · 02-04
首药控股(688197.SH)：MAT2A抑制剂SY-9453获得药物临床试验批准通知书
加载更多
公司概况
公司名称：
首药控股(北京)股份有限公司
所属行业：
医药制造业
上市日期：
2022-03-23
主营业务：
首药控股(北京)股份有限公司的主营业务是肿瘤领域创新小分子疗法的发现与开发。公司的主要产品是技术开发及服务、中间体。公司是我国首家建立起覆盖ALK阳性NSCLC全周期产品组合的企业，是全球少数、国内首个实现多代ALK抑制剂系统布局的创新药企业之一。
发行价格：
39.90
{"stockData":{"symbol":"688197","market":"SH","secType":"STK","nameCN":"首药控股-U","latestPrice":40.21,"timestamp":1779420580000,"preClose":42.67,"halted":0,"volume":1876925,"delay":0,"changeRate":-0.0577,"floatShares":64004900,"shares":149000000,"eps":-0.6266,"marketStatus":"午间休市","change":-2.46,"latestTime":"05-22 11:29:40","open":42.67,"high":43.77,"low":39.23,"amount":76707500,"amplitude":0.1064,"askPrice":40.28,"askSize":4,"bidPrice":40.21,"bidSize":92,"shortable":0,"etf":0,"ttmEps":-0.6266,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779426000000},"marketStatusCode":3,"adr":0,"adjPreClose":42.67,"symbolType":"stock_kcb","openAndCloseTimeList":[[1779413400000,1779420600000],[1779426000000,1779433200000]],"highLimit":46.94,"lowLimit":38.4,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":148719343,"isCdr":false,"pbRate":9.54,"roa":"--","roe":"--","epsLYR":-0.87,"committee":0.273438,"marketValue":5980000000,"turnoverRate":0.0293,"status":1,"floatMarketCap":2574000000},"requestUrl":"/m/hq/s/688197","defaultTab":"news","newsList":[{"id":"2636062419","title":"每周股票复盘：首药控股（688197）SY-5007获益于国产先发优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2636062419","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636062419?lang=zh_cn&edition=full","pubTime":"2026-05-17 04:53","pubTimestamp":1778964786,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，首药控股报收于41.74元，较上周的41.64元上涨0.24%。本周，首药控股5月11日盘中最高价报44.92元。答：感谢您对SY-5007的关注。上述结果表明,SY-5007在初治及经治RET融合阳性NSCLC患者中均展现出较高水平的抗肿瘤活性,并具有良好的缓解持续性趋势。在安全性方面,SY-5007整体耐受性良好。截至目前,SY-5007是临床进展最快的完全国产的选择性RET抑制剂之一,进度优势明显。这将进一步拓展SY-5007的适应症人群,扩大其市场空间。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001629.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635727990","title":"【机构调研记录】金鹰基金调研首药控股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635727990","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635727990?lang=zh_cn&edition=full","pubTime":"2026-05-15 08:02","pubTimestamp":1778803327,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月14日披露的机构调研信息，金鹰基金近期对1家上市公司进行了调研，相关名单如下：1）首药控股 调研纪要：SY-5007在初治和经治RET融合阳性非小细胞肺癌患者中均展现显著抗肿瘤活性，截至2025年4月10日，初治患者ORR为89.3%，经治患者ORR为81.3%，安全性整体可管理。旗下最近一年表现最佳的公募基金产品为金鹰信息产业股票A，最新单位净值为5.43，近一年增长108.81%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500008481.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635727630","title":"【机构调研记录】东方基金调研达瑞电子、首药控股","url":"https://stock-news.laohu8.com/highlight/detail?id=2635727630","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635727630?lang=zh_cn&edition=full","pubTime":"2026-05-15 08:01","pubTimestamp":1778803278,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月14日披露的机构调研信息，东方基金近期对2家上市公司进行了调研，相关名单如下：1）达瑞电子 调研纪要：公司2025年实现营收318,772.06万元，同比增长24.24%；净利润28,215.41万元，同比增长16.72%。2026年Q1营收80,175.70万元，同比增长21.75%；净利润7,197.77万元，同比增长25.80%。维斯德于2025年7月启动收购，11月完成交割，2026年Q1并表，整合顺利，带来积极业绩贡献。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500008426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197","BK0214","300976"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635745202","title":"首药控股：5月1日接受机构调研，海通证券、兴业基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2635745202","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635745202?lang=zh_cn&edition=full","pubTime":"2026-05-14 22:32","pubTimestamp":1778769147,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年5月14日首药控股发布公告称公司于2026年5月1日接受机构调研，海通证券、兴业基金、东方基金、中欧基金、景顺长城基金、金鹰基金、中银资管、东方红资管、博裕资本、大家资产、人保养老、华创证券、投资者、广发证券、国金证券、申万宏源、浙商证券、汇添富基金、万家基金、华宝基金参与。在安全性方面,SY-5007整体耐受性良好。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400043139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06837","BK0239","BK0070","BK0276","600837","BK0188","BK0183","BK0028","BK1147","BK0012","BK1564","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633189751","title":"首药控股（688197）披露2025年度持续督导跟踪报告，5月6日股价上涨0.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633189751","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633189751?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:29","pubTimestamp":1778063354,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，首药控股报收于41.17元，较前一交易日上涨0.78%，最新总市值为61.23亿元。该股当日开盘41.0元，最高41.95元，最低40.37元，成交额达7603.45万元，换手率为2.88%。近日，中信建投证券股份有限公司发布《关于首药控股（北京）股份有限公司2025年度持续督导跟踪报告》。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600032234.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632623944","title":"每周股票复盘：首药控股（688197）营收增119.88%净亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2632623944","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632623944?lang=zh_cn&edition=full","pubTime":"2026-05-02 06:09","pubTimestamp":1777673357,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，首药控股报收于40.85元，较上周的38.2元上涨6.94%。本周，首药控股4月30日盘中最高价报41.82元。公司尚未盈利，存在累计未弥补亏损，主要财务数据显示营业收入同比增长119.88%，净亏损收窄。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628754029","title":"首药控股（688197）2026年一季报简析：营收上升亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2628754029","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628754029?lang=zh_cn&edition=full","pubTime":"2026-04-19 06:08","pubTimestamp":1776550104,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期首药控股发布2026年一季报。根据财报显示，首药控股营收上升亏损收窄。其中，净利率-53.9%，同比增97.88%，销售费用、管理费用、财务费用总计519.64万元，三费占营收比18.56%，每股净资产4.47元，同比减12.29%，每股经营性现金流-0.14元，同比增67.57%，每股收益-0.1元，同比增70.59%证券之星价投圈财报分析工具显示：业务评价：去年的净利率为-1486.39%，算上全部成本后，公司产品或服务的附加值不高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628275970","title":"每周股票复盘：首药控股（688197）股东户数增11.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628275970","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628275970?lang=zh_cn&edition=full","pubTime":"2026-04-19 03:17","pubTimestamp":1776539826,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，首药控股报收于41.3元，较上周的39.39元上涨4.85%。股本股东变化股东户数变动截至2026年3月31日，首药控股股东户数为5589.0户，较2025年12月31日增加581.0户，增幅11.6%。公司公告汇总首药控股（北京）股份有限公司2025年年度报告摘要显示，2025年末资产总额为791,233,717.90元，归属于上市公司股东的净资产为680,178,869.53元。首药控股（北京）股份有限公司2025年度审计报告由天健会计师事务所出具，审计意见为标准无保留意见。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900001132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628202011","title":"首药控股（688197）披露2025年年度报告，4月17日股价下跌1.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628202011","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628202011?lang=zh_cn&edition=full","pubTime":"2026-04-17 22:20","pubTimestamp":1776435626,"startTime":"0","endTime":"0","summary":"截至2026年4月17日收盘，首药控股报收于41.3元，较前一交易日下跌1.81%，最新总市值为61.42亿元。该股当日开盘41.73元，最高41.94元，最低40.67元，成交额达6076.8万元，换手率为2.3%。近日，首药控股（北京）股份有限公司披露《2025年年度报告》。公告显示，截至2025年末，公司资产总额为791,233,717.90元，归属于上市公司股东的净资产为680,178,869.53元。2025年公司实现营业收入8,667,574.64元，较2024年增长119.88%。研发投入占营业收入的比例为2,269.38%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700045992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628014277","title":"首药控股：第一季度净利润亏损1509.08万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628014277","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628014277?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:21","pubTimestamp":1776421274,"startTime":"0","endTime":"0","summary":"首药控股(688197.SH)公告称，2026年第一季度实现营业收入2800万元，同比增长1300.00%；归属于上市公司股东的净利润为-1509.08万元。业绩变动主要系本报告期内公司确认的JAK2抑制剂首笔一次性收益分成2000万元及各合作研发项目里程碑事件顺利达成，收取的里程碑款项同比增加所致。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041700037210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618184545","title":"首药控股跌3.3% 2022年上市募15亿中信建投保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2618184545","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618184545?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:33","pubTimestamp":1773304392,"startTime":"0","endTime":"0","summary":"中国经济网北京3月12日讯 首药控股 今日收报37.77元，跌幅3.30%，总市值56.17亿元。目前该股处于破发状态。 首药控股于2022年3月23日在上交所科创板上市，发行价格为39.90元/股，公开发行股数为3718.00万股，占发行后总股本的比例为25.00%，保荐机构为中信建投证券股份有限公司，保荐代表人为杨慧泽、李彦芝。 首药控股上市发行费用总额为1.10亿元，中信建投证券股份有限公司获得保荐及承销费用9089.57万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260312/32063317.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["601066","BK0276","688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617619663","title":"每周股票复盘：首药控股（688197）调整JAK2抑制剂研发合作获8300万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617619663","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617619663?lang=zh_cn&edition=full","pubTime":"2026-03-08 03:16","pubTimestamp":1772910972,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，首药控股报收于39.37元，较上周的37.0元上涨6.41%。本周，首药控股3月6日盘中最高价报40.76元。调整后，正大天晴将支付公司一次性收益分成8,000万元，并保留原协议中300万元里程碑款项，合计支付8,300万元后视为全部付款义务履行完毕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800001157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617517248","title":"首药控股（688197）披露关于调整JAK2抑制剂类抗肿瘤新药合作研发模式的公告，3月5日股价上涨1.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617517248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617517248?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:21","pubTimestamp":1772702498,"startTime":"0","endTime":"0","summary":"截至2026年3月5日收盘，首药控股报收于37.82元，较前一交易日上涨1.29%，最新总市值为56.25亿元。近日，首药控股（北京）股份有限公司发布《关于调整JAK2抑制剂类抗肿瘤新药的合作研发模式的公告》。公告显示，公司全资子公司赛林泰与正大天晴、润众制药签署《技术开发（合作）合同》补充协议，调整JAK2抑制剂类抗肿瘤新药合作研发模式。知识产权由四方共有调整为正大天晴单独所有，以简化权属关系，降低管理成本与潜在纠纷风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500028003.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616457098","title":"每周股票复盘：首药控股（688197）董事李庭因股东单位内部安排离任","url":"https://stock-news.laohu8.com/highlight/detail?id=2616457098","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616457098?lang=zh_cn&edition=full","pubTime":"2026-03-01 03:13","pubTimestamp":1772305991,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，首药控股报收于37.0元，较上周的38.85元下跌4.76%。本周关注点公司公告汇总：董事李庭因股东单位内部管理安排辞任公司董事职务公司公告汇总首药控股（北京）股份有限公司董事李庭女士因股东单位北京亦庄国际投资发展有限公司的内部管理安排，申请辞去公司第二届董事会董事职务，辞任自2026年2月26日生效。截至公告日，李庭女士未直接或间接持有公司股份，不存在未履行的公开承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001245.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614093850","title":"首药控股（688197）披露董事离任公告，2月27日股价上涨0.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614093850","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614093850?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:43","pubTimestamp":1772206991,"startTime":"0","endTime":"0","summary":"近日，首药控股（北京）股份有限公司发布《关于董事离任的公告》。公告显示，公司董事李庭女士因股东单位北京亦庄国际投资发展有限公司的内部管理安排，申请辞去公司第二届董事会董事职务，辞任自2026年2月26日生效。李庭女士在任期间与公司、董事会及各专门委员会无意见分歧，亦无应披露未披露事项。截至公告日，李庭女士未直接或间接持有公司股份，不存在未履行的公开承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700043541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613713843","title":"首药控股（688197）披露核心技术人员退休离任公告，2月24日股价下跌3.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613713843","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613713843?lang=zh_cn&edition=full","pubTime":"2026-02-24 19:26","pubTimestamp":1771932390,"startTime":"0","endTime":"0","summary":"公告显示，公司核心技术人员HONG LUO因年龄原因申请退休，退休后不再担任公司任何职务。罗鸿先生出生于1959年，曾任公司副总经理、总经理等职，未持有公司股份。公司已与其完成工作交接，研发团队结构完整，后备人员充足，其离任不影响公司技术研发和日常运营，不构成重大不利影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260224/32024362.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613990207","title":"首药控股跌3.84% 2022年上市募15亿中信建投保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2613990207","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613990207?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:21","pubTimestamp":1771924889,"startTime":"0","endTime":"0","summary":"中国经济网北京2月24日讯 首药控股 今日股价收报37.36元，跌幅3.84%。目前该股处于破发状态。 首药控股于2022年3月23日在上交所科创板上市，发行价格为39.90元/股，公开发行股数为3718.00万股，占发行后总股本的比例为25.00%，保荐机构为中信建投证券股份有限公司，保荐代表人为杨慧泽、李彦芝。 首药控股上市发行费用总额为1.10亿元，中信建投证券股份有限公司获得保荐及承销费用9089.57万元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260224/32023780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["601066","BK0276","BK0239","688197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611189365","title":"首药控股2026年关注点：业绩增长与核心产品审评进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2611189365","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611189365?lang=zh_cn&edition=full","pubTime":"2026-02-13 12:05","pubTimestamp":1770955500,"startTime":"0","endTime":"0","summary":"经济观察网首药控股-U(688197)2026年需关注财务披露及核心产品研发进展。业绩经营情况公司于2026年1月30日披露2025年业绩快报，显示营业收入866.76万元，同比增长119.88%，亏损同比收窄。正 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260213/c674790854.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260213/c674790854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609264815","title":"每周股票复盘：首药控股（688197）SY-9453获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2609264815","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609264815?lang=zh_cn&edition=full","pubTime":"2026-02-08 03:11","pubTimestamp":1770491470,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，首药控股报收于36.3元，较上周的35.77元上涨1.48%。本周，首药控股2月2日盘中最高价报37.49元。本周关注点公司公告汇总：SY-9453胶囊获药物临床试验批准通知书。公司公告汇总首药控股（北京）股份有限公司自愿披露，其收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，SY-9453胶囊单药用于治疗甲基硫腺苷磷酸化酶纯合缺失的局部晚期或转移性实体瘤的临床试验申请获批。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688197","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608735285","title":"首药控股(688197.SH)：MAT2A抑制剂SY-9453获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2608735285","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608735285?lang=zh_cn&edition=full","pubTime":"2026-02-04 17:40","pubTimestamp":1770198027,"startTime":"0","endTime":"0","summary":"智通财经APP讯，首药控股(688197.SH)发布公告，公司于近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，SY-9453胶囊单药用于治疗甲基硫腺苷磷酸化酶(MTAP)纯合缺失的局部晚期或转移性实体瘤的临床试验申请获得批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4503","688197","SY","BK0239","BK4077","BK4563"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779424016962,"stockEarnings":[{"period":"1week","weight":0.023},{"period":"1month","weight":0.0813},{"period":"3month","weight":0.0983},{"period":"6month","weight":0.0546},{"period":"1year","weight":0.2219},{"period":"ytd","weight":0.2283}],"compareEarnings":[{"period":"1week","weight":-0.0241},{"period":"1month","weight":-0.0019},{"period":"3month","weight":-0.0012},{"period":"6month","weight":0.0632},{"period":"1year","weight":0.2036},{"period":"ytd","weight":0.0273}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"首药控股(北京)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"5589人(较上一季度增加11.60%)","perCapita":"11451股","listingDate":"2022-03-23","address":"北京市大兴区北京经济技术开发区荣华中路10号1幢19层1单元2202-2号","registeredCapital":"14871万元","survey":" 首药控股(北京)股份有限公司的主营业务是肿瘤领域创新小分子疗法的发现与开发。公司的主要产品是技术开发及服务、中间体。公司是我国首家建立起覆盖ALK阳性NSCLC全周期产品组合的企业，是全球少数、国内首个实现多代ALK抑制剂系统布局的创新药企业之一。","listedPrice":39.9},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"首药控股-U(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供首药控股-U(688197)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"首药控股-U,688197,首药控股-U股票,首药控股-U股票老虎,首药控股-U股票老虎国际,首药控股-U行情,首药控股-U股票行情,首药控股-U股价,首药控股-U股市,首药控股-U股票价格,首药控股-U股票交易,首药控股-U股票购买,首药控股-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"首药控股-U(688197)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供首药控股-U(688197)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}